Abstract
Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.
| Original language | English |
|---|---|
| Pages (from-to) | 123-124 |
| Number of pages | 2 |
| Journal | Clinical Neuropharmacology |
| Volume | 37 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- aripiprazole
- delayed sleep phase syndrome
- depression
- histamine
- insomnia
ASJC Scopus subject areas
- Pharmacology
- Clinical Neurology
- Pharmacology (medical)
- Medicine(all)
Cite this
Aripiprazole is effective for treatment of delayed sleep phase syndrome. / Takaki, Manabu; Ujike, Hiroshi.
In: Clinical Neuropharmacology, Vol. 37, No. 4, 2014, p. 123-124.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Aripiprazole is effective for treatment of delayed sleep phase syndrome
AU - Takaki, Manabu
AU - Ujike, Hiroshi
PY - 2014
Y1 - 2014
N2 - Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.
AB - Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.
KW - aripiprazole
KW - delayed sleep phase syndrome
KW - depression
KW - histamine
KW - insomnia
UR - http://www.scopus.com/inward/record.url?scp=84925354208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925354208&partnerID=8YFLogxK
U2 - 10.1097/WNF.0000000000000035
DO - 10.1097/WNF.0000000000000035
M3 - Article
C2 - 24992089
AN - SCOPUS:84925354208
VL - 37
SP - 123
EP - 124
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
SN - 0362-5664
IS - 4
ER -